CLINICAL_TRIALS
trial_result
· 2014-12-22
Clinical Trial Update: A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) [Phase 3]
Summary
Phase 3 study evaluating V503 vaccine given with REPEVAX in 11- to 15-year-olds completed; results posted in 2014 for papillomavirus infections.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-12-22